LeMaitre (NASDAQ:LMAT) Reports Sales Below Analyst Estimates In Q3 Earnings

Core Insights - LeMaitre Vascular (NASDAQ:LMAT) reported Q3 CY2025 revenue of $61.05 million, an 11.4% increase year on year, but fell short of market expectations [1][6] - The company's Q4 CY2025 revenue guidance of $62.8 million is 2.9% below analysts' estimates [1][6] - GAAP profit per share was $0.75, exceeding analysts' consensus by 31.5% [1][6] Company Overview - Founded in 1983, LeMaitre Vascular develops specialized medical devices for vascular surgeons treating peripheral vascular disease and circulatory conditions [3] Revenue Growth - Over the last five years, LeMaitre achieved a compounded annual growth rate of 14.6%, outperforming the average healthcare company [4] - The company's annualized revenue growth over the last two years was 13.9%, consistent with its five-year trend, indicating strong demand [5] Quarterly Performance - Q3 CY2025 revenue was $61.05 million, missing analyst estimates of $62.3 million by 2% [6] - GAAP EPS was $0.75, surpassing estimates of $0.57 by 31.5% [6] - Adjusted EBITDA was $19.24 million, with a margin of 31.5%, beating estimates by 8.6% [6] - Operating margin improved to 33.3%, up from 24% in the same quarter last year [6] Organic Revenue Analysis - Organic revenue grew by 12% year on year, slightly below the 14.8% growth expected by analysts [6][8] - Over the last two years, LeMaitre's organic revenue averaged 13.4% year-on-year growth, indicating strong core operations [7]